Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants.

NCT04521478 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04521478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants.
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
November 20, 2020
Completion date
February 2, 2024
Enrollment
389 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major